Sai Parenterals Ltd (SAIPARENT) is currently trading at 470.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sai Parenterals is an integrated pharmaceutical company manufacturing injectables, oral solids, liquid orals, topical products and branded generics, while providing export-focused CDMO development and commercial supply. Its business spans India, Australia, New Zealand and other regulated or semi-regulated markets, supported by manufacturing facilities, dossier ownership, regulatory capabilities and distribution relationships. The company’s revenue mix has changed dramatically from predominantly domestic branded generics to CDMO-led international business. CDMO contributed 63% of FY26 revenue versus 5% in FY23, while exports increased from 3% to 63% of revenue from operations, indicating a major strategic shift toward contracted, regulated-market opportunities. Sai Parenterals has assembled unusually strong near-term revenue visibility for its size, with more than half of consolidated revenue contracted under long-term agreements. Noumed’s AUD 232 million Australian OTC book and the Philippines anti-tuberculosis contract provide a foundation for FY27 growth, although execution and manufacturing transition remain critical. The company is replacing constrained Jeedimetla injectable facilities with a larger Gummadidala asset built to EU-GMP and USFDA standards. At the same time, the acquired Sai Prathyak R&D centre provides 174 molecules and 285 SKUs across critical care and oncology, potentially shortening the path from product development to commercial manufacturing. Q2FY27 showed sharp sequential improvement, with revenue rising 9% to Rs. 196.1 crore, EBITDA increasing 67% to Rs. 41.4 crore and EBITDA margin reaching 21.1%. However, depreciation, finance costs and working-capital absorption remain significant, with H1 operating cash flow negative Rs. 205.5 crore during the investment phase.

Over the past 52 weeks, Sai Parenterals Ltd has traded between a low of ₹400.00 and a high of ₹705.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sai Parenterals Ltd has a market capitalization of approximately 2,123.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sai Parenterals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 85.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,123.47 Cr, Sai Parenterals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sai Parenterals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sai Parenterals Ltd is 85.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Sai Parenterals recorded negative Rs 205.5 crore of net cash from operating activities because working-capital changes consumed Rs 254.5 crore. Operating profit before working-capital changes was Rs 53.2 crore, and net direct taxes paid were Rs 4.2 crore.

Sai plans to shift a material share of Noumed’s third-party product sourcing to its own facilities from FY27. The presentation says this would replace an approximately 10% distribution margin with manufacturing margin on the same contracted revenue. Adelaide Phase 1 is planned from Q4FY27, alongside expanded Indian capacity.

Sai Parenterals reported that CDMO products and services accounted for 63% of FY26 net revenue. The share was 20% in FY25 and 5% in FY23. Branded generic formulations made up the remaining 37% of FY26 net revenue.

Sai Parenterals cited restrictions on upgradations under the Hyderabad Industrial Lands Transformation Policy for its Jeedimetla Units I and II. It also said the 3,100-square-yard site was below the 12,000 to 13,000 square yards needed for the intended EU-GMP injectable plant.